Ginsenoside Rb1 Lessens Gastric Precancerous Lesions by Interfering With β-Catenin/TCF4 Interaction
Open Access
- 14 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
Abstract
Background: Seeking novel and effective therapies for gastric precancerous lesions (GPL) is crucial to reducing the incidence of gastric cancer. Ginsenoside Rb1 (GRb1) is a major ginsenoside in ginseng and has been proved to possess multiple bioactivities. However, whether GRb1 could protect against GPL and the underlying mechanisms have not been explored.Methods: We evaluated the effects of GRb1 on gastric precancerous lesions in rats on macroscopic, microscopic and ultramicroscopic levels. Then, an antibody array was employed to screen differential expression proteins (DEPs). Validation for the targeting DEP and investigation for the possible mechanism was conducted using immunohistochemistry, qRT-PCR, TUNEL apoptosis assay, immunoprecipitation and immunoblotting.Results: GRb1 was found to reverse intestinal metaplasia and a portion of dysplasia in the MNNG-induced GPL rats. The antibody array assay revealed seven DEPs in GPL rats as compared to control rats (5 DEPs were up-regulated, while two DEPs were down-regulated). Among the DEPs, β-catenin, beta-NGF and FSTL1 were significantly down-regulated after GRb1 administration. Our validation results revealed that enhanced protein expression and nuclear translocation of β-catenin were present in animal GPL samples. In addition, analysis of human gastric specimens demonstrated that β-catenin up-regulation and nuclear translocation were significantly associated with advanced GPL pathology. GRb1 intervention not only decreased protein expression and nuclear translocation of β-catenin, but interfered with β-catenin/TCF4 interaction. Along with this, declined transcriptional and protein expression levels of downstream target genes including c-myc, cyclin D1 and Birc5 were observed in GRb1-treated GPL rats.Conclusion: GRb1 is capable of preventing the occurrence and progression of GPL, which might be contributed by diminishing protein expression and nuclear translocation of β-catenin and interfering with β-catenin/TCF4 interaction.Funding Information
- Data Center of Management Science, National Natural Science Foundation of China-Peking University
This publication has 40 references indexed in Scilit:
- CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): A focus on its role in cancerThe International Journal of Biochemistry & Cell Biology, 2015
- A Prospective Study of Vitamin and Mineral Supplement Use and the Risk of Upper Gastrointestinal CancersPLOS ONE, 2014
- The many faces and functions of β-cateninThe EMBO Journal, 2012
- Caveolin-1, E-cadherin and β-catenin in gastric carcinoma, precancerous tissues and chronic non-atrophic gastritisChinese Journal of Cancer Research, 2012
- An Anti-Wnt5a Antibody Suppresses Metastasis of Gastric Cancer Cells In Vivo by Inhibiting Receptor-Mediated EndocytosisMolecular Cancer Therapeutics, 2012
- Gastric Cancer Risk in Patients With Premalignant Gastric Lesions: A Nationwide Cohort Study in the NetherlandsGastroenterology, 2008
- Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakiaMolecular Cancer, 2007
- Wnt/β-Catenin Signaling in Development and DiseaseCell, 2006
- Coefficient induction of pepsinogen 1-decreased pyloric glands and gastric cancers in five different strains of rats treated with N-methyl-N′-nitro-N-nitrosoguanidineCarcinogenesis: Integrative Cancer Research, 1988